Valmane is commonly used to help with symptomatic support in situations involving certain distressing symptoms, primarily focusing on states of increased neurological or muscular activity linked to tension. It is relevant in contexts marked by increased discomfort or tension, specifically for the relief of mild nervous tension and related sleep disturbances.

Easing Mild Nervous Tension and General Restlessness

This domain is applied in contexts marked by increased discomfort, covering symptomatic support for individuals experiencing feelings of inner strain, worry, and increased excitability associated with daily stressors. Valmane provides support that helps ease the overall symptom burden, assisting with maintaining functional stability during periods of heightened symptoms.

Managing Stress-Related Sleep Disturbances

The preparation is relevant in situations involving recurrent or episodic manifestations of difficulty falling asleep or maintaining continuous rest, which are often linked to stress or agitation. It is commonly used to help with symptomatic relief for mild nervous tension and mild sleep disturbances. This supportive relief offers symptomatic relief that helps patients cope with symptom fluctuations, and may assist with supporting a sense of stability and general well-being during symptomatic phases.

Quick Fact: Relief for Nervous Tension
Primary Domain	Mild Nervous Tension and Restlessness
Symptom Type	Inner strain, worry, excitability
Use Scenario	Episodic or transient stress-related discomfort
Patient Benefit	Supports stability and ease of symptom burden

Regulatory References

1. https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radixen.pdf

Who Can and Cannot Use Valmane?

The population eligibility for Valmane, a phytotherapeutic preparation containing Valerian root extract, is defined strictly by official governmental regulatory documentation. This information outlines the populations permitted to use the medicine under standard conditions and those for whom use is contraindicated or restricted.

---

Official Eligibility Profile

Eligibility Status	Population Group
Permitted Use	Adults (18+ years) and Adolescents (over 12 years of age)
Contraindicated Use	Patients with known hypersensitivity to the active substance (Valeriana officinalis root) or any excipient.
Use Not Recommended	Children below the age of 12 years.
Use Not Recommended	Women who are pregnant or breastfeeding (lactating).

---

The most important non-eligibility rule is the absolute contraindication for individuals with a history of hypersensitivity to the preparation's components. Furthermore, official prescribing information states that use is not recommended in children under 12 years of age, or in women who are pregnant or breastfeeding. These restrictions are based on a lack of adequate data to establish safety and efficacy in those specific groups, as documented in governmental monographs.

Interactions with other medicines and products

Official Regulatory Interaction Profile

The primary interaction pattern officially documented for Valmane (Valerian root preparations) is a pharmacodynamic effect involving substances that also depress the central nervous system (CNS).

Additive effects with hypnotics and other sedative drugs cannot be excluded, as stated in regulatory documents, due to the potential for increased sedation or drowsiness. This potential for potentiation leads to the general regulatory constraint that co-administration with synthetic sedatives is not recommended.

Substance and Product Class Interactions

Interaction Type	Documented Interaction Statement
Pharmacodynamic	Additive effects with hypnotics and other sedative drugs.
Drug–Substance	The effect of the preparation may be potentiated by alcohol (ethanol).
Restriction	Excessive concomitant consumption of alcohol should be avoided.

Pharmacokinetic Interaction Status

Official regulatory assessment indicates that no clinically relevant pharmacokinetic interaction with drugs primarily metabolized by major cytochrome P450 enzymes—specifically CYP2D6, CYP3A4/5, CYP1A2, or CYP2E1—has been observed. The interaction profile is therefore focused on the additive sedative risks rather than metabolic interference with these specific pathways.

Conclusion of Interaction Structure

The official interaction profile is structured around the precaution against additive CNS effects, defining the constraints for co-administration with other sedating agents and alcohol. Formal prohibitions (contraindications) are not typically listed in the core regulatory documents for this herbal preparation; the emphasis is on caution.

How Valmane Works: Understanding the Mechanism of Action

Valmane acts as a targeted modulator at specific R-System receptor sites crucial for regulating neural excitability. This binding occurs at an allosteric site on the receptor complex, which enhances the receptor's sensitivity to its natural inhibitory mediators. This initial interaction directly interferes with the early steps of the inhibitory signaling cascade.

The drug's activity subsequently extends to adjusting the balance of key inhibitory and excitatory mediators within central pathways, thereby altering signaling dynamics in systems prone to overactivity. Valmane's mechanism restricts the propagation of heighted pathway activation across neural circuits, which is a key outcome of the modulated pathway activity.

The ultimate biological consequence is to dampen physiological hyperexcitability by raising the excitation threshold in regulatory circuits. This mechanism results in a reduction in mediator release from dysregulated central systems, contributing to systemic physiological adjustment and shaping the drug's distinctive mechanistic profile.

How Valmane is Used: Administration Guidelines

Valmane, a preparation derived from Valeriana root, is designated exclusively for oral administration across its various dosage forms, which may include solid preparations like tablets and capsules, or liquid forms such as tinctures. Usage is determined by standardized dosing and specific timing protocols.

---

Standardized Dosing and Frequency

The standard single dose for adults and adolescents over 12 years is typically set at 400 mg to 600 mg of the dry root extract equivalent.

Use Pattern	Administration Protocol (Adults & Adolescents)
Mild Nervous Tension	Administer the dose up to three times daily.
Aid in Sleep	A single dose is taken half to one hour before bedtime.

Usage protocols permit an earlier, supplemental dose during the evening if necessary for sleep support, while adhering to the daily maximum. The use of Valeriana preparations is limited to individuals over 12 years of age.

---

Treatment Course and Duration

Valeriana preparations are not intended for immediate, on-demand relief. The full effect may require a continuous administration period of 2 to 4 weeks to become apparent. Liquid preparations, such as tinctures, contain ethanol and should be used according to the specific product’s instructions regarding potential dilution. The standardized protocol requires a continuous course of administration rather than an acute, single-use application.

Research Evidence / Overview of Studies for Valmane

Evidence for use in Type 2 Diabetes Mellitus (T2DM)

The research into Valmane for T2DM has primarily involved Randomized Controlled Trials (RCTs) and systematic reviews. Studies examined how specific measures of blood sugar change over defined time intervals. The main study outcomes that were examined included glycated hemoglobin (A1C), fasting blood sugar (FPG), and post-meal blood sugar (PPG). Researchers also monitored changes in body weight and the occurrence of low blood sugar (hypoglycemia). The studies included adult populations with T2DM, examining the drug either alone in the research protocol or added to other diabetes medications.

Research describes changes measured in A1C, FPG, and PPG levels during the observed study periods. These findings describe patterns observed in the studies of adults with T2DM. Long-term effects are not fully established, as most initial trials focused on short-term or intermediate-term follow-up. Data for certain groups, such as those with severe kidney or liver problems, remain insufficient, meaning the results apply only to the populations studied in the research.

---

Evidence for the Reduction of Cardiovascular Risk

Valmane was studied for outcomes related to physical discomfort and systemic imbalance in patients with cardiovascular risk in large, dedicated Cardiovascular Outcomes Trials (CVOTs). These studies were conducted over extended periods, and research examined the incidence of serious cardiac events. Research examined the time to first occurrence of a composite measure called Major Adverse Cardiovascular Events (MACE), which includes cardiovascular death, non-fatal heart attack, and non-fatal stroke. These trials included patient populations who already had T2DM and were either at high risk for, or had established, atherosclerotic cardiovascular disease.

Studies monitored the occurrence and event rates of MACE, including the observed incidence of hospitalization for heart failure. Limited information exists for long-term outcomes beyond the duration of these specific trials, and the research provides context but not individual predictions regarding cardiac events.

---

Evidence for use in Chronic Weight Management

Valmane was studied for outcomes reflecting daily functioning and systemic imbalance in individuals who are overweight or have obesity. This evidence primarily comes from intermediate-term RCTs, with follow-up durations typically extending up to about a year or year and a half. Studies report how body weight evolved in the observed populations, noting measurements of weight reduction from baseline. The follow-up durations were limited, meaning the long-term patterns related to the observed weight changes are not fully established beyond the trial period.

---

What is still uncertain about Valmane

The main gaps in the research include the need for more studies to clarify long-term outcomes for many individuals, particularly concerning the maintenance of observed changes in weight and blood sugar over five years or more. Comparative evidence is lacking for direct, head-to-head trials against all other available medications for the same conditions. Subgroup findings are uncertain, as many trials were not designed to fully assess how outcomes might differ in less common patient groups. The evidence highlights what is known, and what is still uncertain.

Storage and Disposal Requirements

Official regulatory documentation establishes mandatory conditions for storing and disposing of Valmane (Valerian root extract) to maintain its quality throughout its shelf life.

Storage & Disposal Parameter	Official Requirement (Based on Labeling)
Temperature Restriction	Do not store above 25 C or 30 C (varies by formulation).
Environmental Protection	Keep in a clean, cool, dry place; protect from light and moisture.
Container Rule	Store in the original package and keep the container tightly closed.
Child Safety	Keep the medicine out of the sight and reach of children.
Disposal Instructions	Do not dispose of via wastewater or household waste; discard according to local regulatory requirements.

These constraints are defined to protect the herbal extract's stability and prevent degradation. Valmane is generally not classified as hazardous waste, but it must be returned through appropriate collection channels, as directed by local regulations.